Edition:
United Kingdom

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

13.97USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$13.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$19.28
52-wk Low
$12.44

Summary

Name Age Since Current Position

Tillman Gerngross

Co-Founder, Chairman of the Board

Rene Russo

2015 President, Chief Executive Officer, Director

Eszter Nagy

2016 Co-Founder, Chief Scientific Officer, Director

Errik Anderson

2015 Co-Founder

Michael Gray

45 Chief Financial Officer, Chief Business Officer

Biographies

Name Description

Tillman Gerngross

Dr. Tillman U. Gerngross, Ph.D., is a Co-Founder and Chairman of the Board of the Company. He is a Co-Founder and Chief Executive Officer for Adimab, LLC and GyycoFi, Inc. He is a Professor of Bioengineering, Darmouth College, United States. He is a Venture Partner for SV Life Science, United States.

Rene Russo

Ms. Rene Russo Pharm.D., is a President, Chief Executive Officer, Director of the company.Russo, PharmD, BCPS, has spent more than 15 years in anti-infective R&D and has leadership experience across all phases of drug development, including global commercial launches for five novel antibacterial agents and clinical development and registration of several antiviral, antibacterial, and antifungal therapeutics. Her work has spanned the earliest phases of in vitro and animal work to clinical pharmacology, clinical development, and post-marketing clinical outcomes research. Prior to Arsanis, Dr. Russo served in various roles over an 11-year period at Cubist Pharmaceuticals (Cubist). As Vice President of an 80+ person global team, Dr. Russo oversaw the clinical microbiology program (including extensive in vitro and animal work to support dose selection and PK/PD analyses), contributed to the design of multiple Phase 1 to Phase 3 clinical studies, and directly managed the oversight of several global burden of disease programs, including urosepsis and nosocomial pneumonia, to understand the outcomes and unmet medical needs in these infectious diseases. In her role at Cubist, she was also responsible for the oversight of more than 140 studies designed to further understand Gram-positive and Gram-negative infections, including epidemiology, resistance patterns, and the study of various treatments (including combination therapies) across nonclinical and clinical studies. Dr. Russo received her PharmD and Bachelor of Science in Pharmacy from Rutgers University and holds a Board of Pharmacy Specialties Pharmacotherapy Certification (BCPS).

Eszter Nagy

Dr. Eszter Nagy M.D., Ph.D. is a Co-Founder, Chief Scientific Officer, Director of the company. Prior to Arsanis, Dr. Nagy served in various roles during her 12 years at Intercell AG. As Senior Vice President and Global Head of Research for Intercell. Dr. Nagy co-founded EveliQure Biotechnologies (Vienna) in 2012, and was on the Board of Directors of WittyCell, S.A.S (now part of Abivax, SE), both are vaccine development companies. Prior to joining the biotechnology industry, Dr. Nagy spent 10 years in academic research. She is habil. professor at the University of Vienna, training graduate students and author of over 60 scientific publications. She was Associate Professor at University Medical School of Pécs and a Visiting Scientist in the Department of Cancer Genetics at the Roswell Park Cancer Institute. Dr. Nagy received her MD and PhD from University Medical School of Pécs, Hungary, and was a Postdoctoral Fellow at Dartmouth Medical School.

Errik Anderson

Mr. Errik B. Anderson is a Co-Founder of the Company. He is Co-Founder, COO/President at Compass Therapeutics, LLC, US Previously, Co-founder and COO, Adimab, LLC, US Lehman Brothers Venture Capital (now Tenaya Capital), US Tuck School of Business, US Founder and President, Seven West Ventures, US.

Michael Gray

Mr. Michael P. Gray, CPA, is a Chief Financial Officer and Chief Business Officer of the Company. Michael Gray has nearly 20 years of industry business development and financial leadership experience, including financial strategy, planning, and operations Prior to Arsanis, Mr. Gray spent 15 years in leadership positions at Curis, Inc including Chief Financial Officer, Chief Business Officer, and Chief Operating Officer. Previously, Mr. Gray held positions including Controller and de facto Chief Financial Officer of Reprogenesis. Mr. Gray has also served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray holds an active Certified Public Accountant license (Rhode Island). He earned his M.B.A. in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College and a Bachelor of Science in accounting from Bryant College.

Basic Compensation

Options Compensation